Valuation: Vivos Therapeutics, Inc.

Market Cap 2.69M 2.4M 2.22M 2.01M 3.76M 255M 3.82M 26.7M 10.57M 134M 10.09M 9.88M 422M P/E 2026 *
-0.1x
P/E 2027 * -0.16x
Enterprise Value 2.69M 2.4M 2.22M 2.01M 3.76M 255M 3.82M 26.7M 10.57M 134M 10.09M 9.88M 422M EV / Sales 2026 *
0.12x
EV / Sales 2027 * 0.08x
Free-Float
88.68%
Yield 2026 *
-
Yield 2027 * -
1 day+0.91%
1 week+1.98%
Current month-9.60%
1 month-8.11%
3 months-65.99%
6 months-84.13%
Current year-93.41%
1 week 0.12
Extreme 0.124
0.14
1 month 0.12
Extreme 0.124
0.16
Current year 0.12
Extreme 0.124
2.69
1 year 0.12
Extreme 0.124
3.05
3 years 0.12
Extreme 0.124
48.79
5 years 0.12
Extreme 0.124
106.75
10 years 0.12
Extreme 0.124
360.25
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - -
Chief Operating Officer - 01/09/2016
Chief Executive Officer 68 01/09/2016
Director TitleAgeSince
Chairman 68 01/06/2020
Director/Board Member 87 01/06/2020
Director/Board Member 59 01/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
14/9/26 Other

Director

12,000 0.0596%
14/9/26 Free

Director

12,000 0.0596%
31/7/26 Free

Chief Financial Officer

400,000 2.8788%
Change 5-day change 1-year change 3-year change Capi.($)
+0.91%+1.98%-95.56%-97.96% 2.69M
+1.16%-1.13%-18.25%+9.38% 179B
+0.02%+4.24%-19.55%+15.88% 118B
-1.22%+0.70%+1.86%+32.59% 117B
+2.29%+17.36%-42.18%+8.22% 93.26B
-2.21%-2.91%-0.51%+75.12% 63.16B
-1.06%+1.75%+13.48%+74.12% 55.68B
-0.75%+3.73%+7.04%-23.26% 54.18B
-1.13%+0.00%-12.56%+30.09% 44.15B
+0.17%+5.85%-5.20%-11.43% 33.95B
Average -0.18%+3.44%-17.14%+11.27% 75.84B
Weighted average by Cap. -0.00%+3.09%-11.77%+21.99%

Financials

2026 *2027 *
Net sales 21.79M 19.46M 17.98M 16.29M 30.48M 2.07B 30.98M 216M 85.64M 1.08B 81.77M 80.03M 3.42B 34.09M 30.44M 28.12M 25.48M 47.68M 3.24B 48.47M 338M 134M 1.7B 128M 125M 5.35B
Net income -23.53M -21.01M -19.41M -17.59M -32.91M -2.23B -33.46M -234M -92.49M -1.17B -88.32M -86.44M -3.69B -14.7M -13.13M -12.13M -10.99M -20.57M -1.4B -20.91M -146M -57.79M -731M -55.18M -54.01M -2.31B
Net Debt - -
Projected Income Statement - Annual - Vivos Therapeutics, Inc.
Logo Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods that promote sleep wellness and health for patients suffering from breathing and sleep issues such as obstructive sleep apnea (OSA) and snoring in adults. The Company's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The Company's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The Company has sleep testing centers and associated medical sleep practice.
Employees
268
Date Price Change Volume
23/10/26 USD 0.1337 +0.91% 936,317
22/10/26 USD 0.1325 -1.63% 1,927,622
21/10/26 USD 0.1347 -4.20% 4,717,135
20/10/26 USD 0.1406 +4.23% 76,703,159
19/10/26 USD 0.1349 +2.90% 47,333,843
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Vivos Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.1337USD
Average target price
2.117USD
Spread / Average Target
+1,483.15%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Vivos Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. VVOS Stock